LGVN - Longeveron ends record rally with appointment of new medical chief

After sharp gains last week, the clinical-stage biotech, Longeveron (LGVN -9.7%) closed lower for the second straight session on Tuesday after the company announced the appointment of Chris Min as its Chief Medical Officer (CMO). Longeveron (NASDAQ:LGVN) shares recorded the third-best weekly gain last week on the back of peer-reviewed data on its Alzheimer’s disease candidate Lomecel-B. In an announcement Tuesday, the company said that its global R&D efforts would be led by Dr. Min effective Monday. His role includes leadership on plans to advance the lead candidate Lomecel-B into pivotal stage trials and towards regulatory approval, the company added. “As a board-certified neurologist with deep clinical experience, Chris will be instrumental in guiding our Alzheimer’s development program,” Chief Executive Geoff Green said. Dr. Min joins Longeveron (LGVN) from Enterin Inc., where he served as the Head of Medical & Clinical Development. See how company shares have performed during the year.

For further details see:

Longeveron ends record rally with appointment of new medical chief